Results 171 to 180 of about 11,112,016 (340)

The Suitability of Direct Medical Costs with INA-CBG'S Claims of Outpatient Breast Cancer in Class A and B Hospitals

Jurnal Ilmu Kesehatan Masyarakat
BPJS Kesehatan noted that cancer financing claims reached IDR 3.5 trillion, ranking second after heart disease. This study aimed to determine the difference in direct medical costs with Indonesian-Case Base Groups (INA-CBGs) claims of outpatient breast ...
Diesty Anita Nugraheni, Fanyda Amiyassin Hafi'ah, May Syahra Indah Permata Harlin, Aji Tetuko, Titik Rahayu Indarti, Gita Mayasari   +5 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Medical Direct Cost of Glaucoma in Morocco

OALib, 2023
Moncef Maiouak, Habiba El Ouazzani Taybi, Mohamed Berraho, Meriem Abdellaoui, Samira El Fakir, Idriss Benatiya Andaloussi, Nabil Tachfouti   +6 more
openaire   +1 more source

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni, Cecile Pagan, Antony Citterio‐Quentin, Isabelle Rouvet, Giulia Dingeo, Cyril Hanin, Claudine Laurent‐Levinson, Samia Pichard, Bénédicte Héron, Clément Gourguechon, Daniele Mandia, Jerome Guitton, Carole Lacout, Nicolas Schleinitz, Florient Potier, Olivier Flabeau, Elsa Besse‐Pinot, Foudil Lamari, Magali Pettazzoni, Yann Nadjar   +19 more
wiley   +1 more source

Annual direct medical costs for diabetes-related events and adverse events (2015 Chinese value).

, 2016
Annual direct medical costs for diabetes-related events and adverse events (2015 Chinese value).
Hengjin Dong (398458), Suodi Zhai (3328581), Shuyan Gu (736892), Xuemei Zhen (3328584), Yiming Mu (288855), Yuhang Zeng (3328578)   +5 more
core   +1 more source

Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era

ClinicoEconomics and Outcomes Research, 2012
Erika Catay,1 Cecilia Castel del Cid,1 Lorena Narváez,1 Edson J Velozo,1 Javier E Rosa,1,2 Luis J Catoggio,1,2 Enrique R Soriano1,21Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, 2University Institute Hospital
Catay E, Castel del Cid C, Narváez L, Velozo EJ, Rosa JE, Catoggio LJ, Soriano ER   +6 more
doaj  

Screening Routine Clinical Notes for Epilepsy Surgery Candidates Using Large Language Models

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epilepsy surgery is severely underutilized despite proven efficacy, with substantial under‐referral of eligible patients in routine clinical practice. This study evaluated the potential role of large language models (LLMs) as decision‐support tools for screening unstructured clinical notes to identify epilepsy surgery candidates and ...
Uriel Fennig, Nadav Amir, Maya Schiller, Roni Loebenstein, Johnatan Nissan, Marina Boxer, Shany Guly Gofrit, Gal Goshen, Sándor Beniczky, Nicola Maggio   +9 more
wiley   +1 more source

Multivariate analysis of the determinants of direct medical costs (multiple linear regression).

, 2019
Multivariate analysis of the determinants of direct medical costs (multiple linear regression).
Delphine Héquet (3445013), Bernard Asselain (111822), Thuy Nguyen (160049), Helene Berseneff (4521235), Sandrine Baffert (5680019), Roman Rouzier (78764), Aline Combes (6940178), Cyrille Huchon (696762), Anne-Laure Soilly (5680022), Caroline Trichot (6940175), Karine Alves (6940181)   +10 more
core   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw, Karishma Randhave, Ekta Anand, Ziang (Debbie) Song, Wangzhen Shen, Jing‐Qiong Kang   +5 more
wiley   +1 more source

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit, Chiranth K. Nagaraj, Jackson S. Newell, Kim Truc Nguyen, Xilal Y. Rima, Jacob Doon‐Ralls, Eduardo Reátegui, Jeffrey M. Statland, Rabi Tawil, Kevin M. Flanigan, Scott Q. Harper, Nizar Y. Saad   +11 more
wiley   +1 more source